Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash & Equivalents: 2014-2024

Historic Cash & Equivalents for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to $26.7 million.

  • Viking Therapeutics' Cash & Equivalents rose 99.37% to $100.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.4 million, marking a year-over-year increase of 99.37%. This contributed to the annual value of $26.7 million for FY2024, which is 51.95% down from last year.
  • As of FY2024, Viking Therapeutics' Cash & Equivalents stood at $26.7 million, which was down 51.95% from $55.5 million recorded in FY2023.
  • Viking Therapeutics' Cash & Equivalents' 5-year high stood at $246.1 million during FY2020, with a 5-year trough of $26.4 million in FY2021.
  • In the last 3 years, Viking Therapeutics' Cash & Equivalents had a median value of $36.6 million in 2022 and averaged $39.6 million.
  • As far as peak fluctuations go, Viking Therapeutics' Cash & Equivalents tumbled by 89.29% in 2021, and later surged by 51.55% in 2023.
  • Yearly analysis of 5 years shows Viking Therapeutics' Cash & Equivalents stood at $246.1 million in 2020, then plummeted by 89.29% to $26.4 million in 2021, then skyrocketed by 38.91% to $36.6 million in 2022, then spiked by 51.55% to $55.5 million in 2023, then crashed by 51.95% to $26.7 million in 2024.